嵌合胚胎与整倍体胚胎移植后PGT-A的系统综述与荟萃分析
该系统综述与荟萃分析纳入8项研究,比较PGT-A后嵌合胚胎与整倍体胚胎移植的生殖结局。汇总分析显示嵌合胚胎活产/持续妊娠率较低(RR 0.74),流产率较高(RR 1.57),但唯一前瞻性双盲试验显示各嵌合等级结局等效。异常类型是最一致的预后修饰因素,节段性嵌合接近整倍体结局。
要点
- 嵌合胚胎移植活产/持续妊娠率低于整倍体(RR 0.74),但唯一双盲试验显示等效。
- 节段性嵌合结局接近整倍体(RR 0.90),全染色体嵌合显著较差(RR 0.60)。
- 嵌合复杂程度呈剂量反应,复杂≥3条染色体持续妊娠/活产率仅20.8%。
核心结论
- 汇总分析中嵌合胚胎移植活产/持续妊娠率低于整倍体胚胎,但唯一前瞻性双盲试验显示各嵌合等级结局等效,提示适应证混杂可解释部分差异。
- 节段性嵌合预后接近整倍体,全染色体嵌合显著较差,嵌合复杂程度呈剂量反应关系。
研究设计与样本
- PRISMA系统综述与荟萃分析,纳入8项研究,共1904例嵌合胚胎移植和9332例整倍体胚胎移植。
- 预先解决重叠队列,并按嵌合水平、异常类型、染色体复杂性和剂量方向(三体 vs 单体)进行预设亚组分析。
主要发现
- 嵌合移植汇总活产/持续妊娠率较低(RR 0.74,95% CI 0.64-0.85;I²=78%;95%预测区间0.41-1.34)。
- 唯一前瞻性双盲试验(胚胎分类对医患设盲)显示所有嵌合等级结局等效(RR 0.98;非劣效性成立)。
- 汇总分析中流产率较高(RR 1.57,95% CI 1.05-2.35;I²=72%)。
- 异常类型是最一致的预后修饰因素:节段性嵌合接近整倍体(RR 0.90,95% CI 0.81-1.00;I²=28%),全染色体嵌合显著较差(RR 0.60,95% CI 0.53-0.68;I²=22%;交互P<0.001)。
- 观察到复杂性剂量反应:持续妊娠/活产率节段性嵌合43.1% > 单条全染色体嵌合32.5% > 双条全染色体嵌合27.2% > 复杂≥3条染色体20.8%,整倍体52.3%(P<0.0001)。
关键数值与推荐
- 嵌合胚胎移植活产/持续妊娠率RR 0.74(95% CI 0.64-0.85),流产率RR 1.57(95% CI 1.05-2.35)。
- 节段性嵌合RR 0.90(95% CI 0.81-1.00),全染色体嵌合RR 0.60(95% CI 0.53-0.68),交互P<0.001。
- 持续妊娠/活产率:节段性嵌合43.1%、单条全染色体32.5%、双条全染色体27.2%、复杂≥3条20.8%、整倍体52.3%(P<0.0001)。
临床怎么用
- 在无整倍体胚胎可选时,可参考嵌合类型与复杂性进行优先排序:节段性嵌合优先于全染色体嵌合,单条优于多条,复杂≥3条预后最差。
- 咨询时应告知汇总分析显示嵌合胚胎结局较差但唯一双盲试验显示等效,证据存在异质性。
- 产科和围产期结局令人安心但证据确定性低或极低,需个体化评估。
局限性
- 汇总分析存在高异质性(I²=78%),主要来自适应证混杂。
- 仅一项前瞻性双盲试验,多数为回顾性研究。
- 产科和围产期结局证据确定性低或极低。
- 亟需具备产科随访的前瞻性登记研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mosaic embryos detected by preimplantation genetic testing for aneuploidy (PGT-A) are increasingly transferred when no euploid alternatives exist, yet their reproductive potential relative to euploid embryos remains contested. A preferred reporting items for systematic reviews and meta-analyses (PRISMA) systematic review and meta-analysis of eight studies was conducted (1904 mosaic and 9332 euploid transfers). Overlapping cohorts were resolved a priori, and pre-specified subgroup analyses were conducted by mosaicism level, aneuploidy type, chromosomal complexity and dosage direction (trisomy versus monosomy). Pooled live birth and ongoing pregnancy rate was lower for mosaic transfers (RR 0.74, 95% CI 0.64 to 0.85; I² = 78%; 95% prediction interval: 0.41 to 1.34). The only prospective double-blind trial in which embryo classification was concealed from clinicians and patients found equivalent outcomes across all mosaic grades (RR 0.98; non-inferiority confirmed), suggesting that confounding by indication substantially explained the observed difference. Miscarriage rate was higher in the pooled analysis (RR 1.57, 95% CI 1.05 to 2.35; I² = 72%). Aneuploidy type was the most consistent prognostic modifier: segmentary mosaicism approached euploid outcomes (RR 0.90, 95% CI 0.81 to 1.00; I² = 28%), whereas whole-chromosome mosaicism was significantly worse (RR 0.60, 95% CI 0.53 to 0.68; I² = 22%; interaction P < 0.001). A complexity dose-response was observed (ongoing pregnancy and live birth rate: segmental mosaic 43.1% > single whole chromosome mosaic 32.5% > double whole chromosome mosaic 27.2% > complex ≥3 chromosomes 20.8% versus euploid 52.3%, P < 0.0001). Obstetric and perinatal outcomes were reassuring but of low or very low certainty. An evidence-based prioritization hierarchy is supported; prospective registries with obstetric follow-up are urgently needed.
引用
- Cristóbal Quevedo I, Cristóbal Garcia I. Mosaic embryo transfer versus euploid embryo transfer after PGT-A: a systematic review and meta-analysis. Reprod Biomed Online. 2026. PMID: 42600547. doi:10.1016/j.rbmo.2026.105872
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。